INDIVIDUAL TEST 992
Beta-Amyloid 42
Indication
Suspicion of Alzheimer's disease or memory investigation
Sample material
CSF
- Minim. volume: 0,5 mL
Transport
- Within Sweden: frozen
- International: frozen
Method
Chemiluminescence enzyme immunoassay (CELEIA)
Reference interval
>620 ng/L (≥50 years)
Result
Results are reported as concentration (ng/L).
Interpretation
Beta-amyloid 42 is the major component of amyloid plaques, and the level in CSF decreases with plaque formation. Low levels is typical of Alzheimer's disease.
References
- Hansson O et al. Alzheimers Res Ther. 2019. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease. PMID: 31010420
- Dumurgier J et al. Alzheimers Res Ther. 2015. Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. PMID: 26034513
- Woyk K et al. J Alzheimers Dis Rep. 2025. The relationship of 18F-FDG-PET to other common biomarkers of dementia in a clinical cohort with memory deficits. PMID: 40290782
- Amft M et al. Alzheimers Res Ther. 2022. The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort. PMID: 35473631
Last updated: 2025-12-05
Can't find what you're looking for? We are here to help
ENSKILD ANALYS 992
Beta-Amyloid 42
Indikation
Misstanke om Alzheimers sjukdom och vid minnesutredning
Provmaterial
Likvor
- Minim. volym: 0,5 mL
Transport
- Inom Sverige: fryst
- Internationellt: fryst
Metod
Kemiluminescens enzymimmunanalys (CELEIA)
Referensintervall
> 620 ng/L (≥50 år)
Resultat
Resultat anges som koncentration (ng/L).
Tolkning
Beta-amyloid 42 är huvudkomponenten i amyloida plack och nivån i likvor sjunker vid plackbildning. Låga nivåer är typiskt vid Alzheimers sjukdom.
Referenser
- Hansson O et al. Alzheimers Res Ther. 2019. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease. PMID: 31010420
- Dumurgier J et al. Alzheimers Res Ther. 2015. Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. PMID: 26034513
- Woyk K et al. J Alzheimers Dis Rep. 2025. The relationship of 18F-FDG-PET to other common biomarkers of dementia in a clinical cohort with memory deficits. PMID: 40290782
- Amft M et al. Alzheimers Res Ther. 2022. The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort. PMID: 35473631
Senast uppdaterat: 2025-12-05